Global Chronic Pain Market - 2025 - 2032

Global Chronic Pain Market - 2025 - 2032

The global chronic pain market reached US$75.42 billion in 2024 and is expected to reach US$124.14 billion by 2032, growing at a CAGR of 6.9 % during the forecast period 2025-2032.

Chronic pain is defined as pain that persists for more than three months and can arise from various conditions, including injuries, surgeries, and diseases like arthritis. The U.S. Centers for Disease Control and Prevention (CDC) reports that about 6.9% of adults experience high-impact chronic pain (HICP), which severely restricts their ability to engage in daily activities.

The statement regarding the burden of chronic pain and the limited access to treatment highlights a significant issue within the healthcare system. This statement indicates that KEM Hospital's pain outpatient department (OPD) sees approximately 1,000 patients annually, with around 80% of these patients requiring some form of intervention or procedure to manage their chronic pain effectively. This scenario sheds light on several critical aspects of chronic pain management.

Chronic pain is a significant global health issue, affecting hundreds of millions of individuals worldwide. Defined as pain that persists for longer than three months, chronic pain can severely impact a person's quality of life and daily functioning. Current estimates suggest that approximately 10% of the global population experiences chronic pain, translating to more than 800 million people. These factors have driven the global chronic pain market expansion.

Market Dynamics: Drivers & Restraints

Advancements in Pain Management Technologies

The advancements in pain management technologies are significantly driving the growth of the global chronic pain market. It is expected to drive throughout the market forecast period.

Technological innovations in healthcare are significantly reshaping the management of chronic pain, utilizing digital health technologies to enhance patient care and improve outcomes. The integration of tools such as wearable devices, mobile applications, virtual reality (VR), and artificial intelligence (AI) is transforming how chronic pain is assessed, monitored, and treated.

These devices track physiological metrics such as heart rate, activity levels, and sleep patterns. They provide real-time feedback to both patients and healthcare providers, enabling better monitoring of pain conditions and facilitating timely interventions. Pain management apps allow patients to log their pain levels, identify triggers, and document responses to treatments. This data is crucial for developing personalized treatment plans tailored to individual patient needs.

Remote patient monitoring enables healthcare providers to collect and analyze patient data outside traditional clinical settings. This is particularly beneficial for chronic pain patients who may face barriers like geographical distance or mobility issues. RPM facilitates timely interventions based on real-time data, leading to improved patient engagement and outcomes.

Furthermore, key players in the industry research activities, initiatives, and launches that would drive this chronic pain market growth. For instance, in May 2023, recent research funded by the National Institutes of Health (NIH) made significant strides in understanding chronic pain by identifying specific brain signatures associated with this condition. For the first time, researchers have successfully recorded pain-related data directly from the brains of individuals suffering from chronic pain disorders, such as those resulting from stroke or phantom limb pain. This innovative study aims to unravel how pain is represented in brain activity and how this knowledge can be leveraged to develop new treatments for chronic pain.

Similarly, in May 2023, the Hospital Clínic in Barcelona recently launched a dedicated healthcare unit focused on treating chronic pain, marking a significant advancement in the management of this complex condition. This new Pain Unit is part of the Anaesthesiology, Resuscitation, and Pain Treatment Service and has been designed with input from both patients and healthcare professionals, in collaboration with the architecture firm AheadPSP.

Also, in November 2023, The UC Gardner Neuroscience Institute launched an advanced clinical trial focused on personalized pain management, particularly for patients undergoing spinal surgery. This initiative aims to enhance post-surgical pain control, reduce reliance on opioids, and shorten hospital stays by tailoring pain management strategies to individual genetic profiles. All these factors demand the global chronic pain market.

Moreover, the rising demand for telemedicine expands the global chronic pain market expansion.

Stringent Regulatory Environment

The stringent regulatory environment will hinder the growth of the global chronic pain market. The lengthy approval processes mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have a profound impact on the global chronic pain market. While these processes are essential for ensuring the safety and efficacy of new medications and medical devices, they also present several challenges that can hinder market growth.

Regulatory agencies implement stringent standards to ensure that new drugs and medical devices are safe and effective before they reach the market. This comprehensive review process typically involves several stages, including pre-authorization assessments, extensive clinical trials, and thorough documentation. The objective is to minimize risks associated with new treatments, particularly for chronic pain conditions where patient safety is critical. However, these rigorous requirements can significantly delay the introduction of potentially beneficial therapies.

The clinical trial process often spans several years, requiring multiple phases of testing to evaluate a treatment's efficacy and safety comprehensively. For example, the FDA's New Drug Application (NDA) pathway necessitates detailed evidence demonstrating a drug's safety and effectiveness before it can be approved for public use. This extended timeline can leave patients waiting for new treatments while continuing to experience chronic pain, which may lead to reliance on existing therapies that are not as effective or have undesirable side effects. Thus, the above factors could be limiting the global chronic pain market's potential growth.

Segment Analysis

The global chronic pain market is segmented based on type, treatment type, distribution channel, and region.

Type:

The neuropathic pain segment is expected to dominate the global chronic pain market share

The neuropathic pain segment holds a major portion of the global chronic pain market share and is expected to continue to hold a significant portion of the global chronic pain market share during the forecast period.

The rising incidence of chronic diseases, particularly diabetes and cancer, is driving demand for effective neuropathic pain management solutions. As the population ages, the number of individuals experiencing neuropathic pain is expected to rise significantly. In the U.S., approximately 65% of adults aged 65 and older report suffering from chronic pain, with a substantial portion attributed to neuropathic causes.

Neuropathic pain encompasses a variety of treatment options, including anticonvulsants (such as gabapentin and pregabalin), antidepressants (like amitriptyline), opioids, and topical treatments such as capsaicin patches. These medications target different pathways involved in pain perception and provide relief for many patients.

Furthermore, major players in the industry have innovative launches and approvals that would drive this segment's growth in the global chronic pain market. For instance, in January 2023, Neuralace Medical received FDA clearance for its innovative Axon Therapy, designed to treat chronic painful diabetic neuropathy (PDN). This approval is significant as it marks the first time a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment has been authorized for PDN, offering a new approach to pain management for millions of individuals suffering from this condition.

Also, in January 2022, Medtronic plc received FDA approval for its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator, both designed for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). This approval expands treatment options for patients suffering from DPN, a common complication of diabetes that affects approximately 30% of individuals with the condition. These factors have solidified the segment's position in the global chronic pain market.

Geographical Analysis

North America is expected to hold a significant position in the global chronic pain market share

North America holds a substantial position in the global chronic pain market and is expected to hold most of the market share.

Chronic pain affects millions of individuals across North America, with conditions such as arthritis, fibromyalgia, neuropathic pain, and cancer-related pain being particularly common. Approximately 50 million adults in the U.S. experience chronic pain, highlighting an urgent need for effective treatment options. This high prevalence drives demand for chronic pain management therapies and significantly contributes to market growth.

According to the Regents of the University of Colorado news in September 2024, The Centers for Disease Control and Prevention (CDC) reported that in 2021, approximately 20% of U.S. adults over 50 million people were experiencing chronic pain. Among these individuals, about 7% were classified as having high-impact chronic pain (HICP), which is defined as pain that significantly limits daily activities and functional capabilities.

Similarly, as per Abbott news in December 2022, Chronic pain is a significant health issue in the United States, affecting more than 50 million adults, which accounts for approximately 20% of the adult population. According to the U.S. Pain Foundation, chronic pain is the leading reason people seek medical attention, contributing to an estimated $635 billion annually in healthcare costs, disability, and lost productivity. This highlights not only the prevalence of chronic pain but also its profound economic impact on society.

North America boasts a well-established healthcare infrastructure that facilitates access to a diverse range of pain management therapies. The presence of specialized healthcare systems and pain clinics ensures that patients receive comprehensive care, including innovative treatment options. Innovations in healthcare technology are transforming chronic pain management. The integration of telemedicine, artificial intelligence (AI), and wearable devices allows for improved monitoring and personalized treatment plans.

Pharmaceutical companies are increasingly focusing on developing alternative therapies, including non-opioid medications and innovative delivery systems. This shift toward safer pain management solutions expands the treatment options available to patients and contributes to chronic pain market growth.

Furthermore, a major number of key players' presence, government initiatives, and launches & approvals would drive this chronic pain market growth. For instance, in August 2024, the National Institutes of Health (NIH) initiated a program aimed at empowering Native American communities to lead public health research focused on addressing issues related to overdose, substance use, and pain, along with associated factors such as mental health and wellness.

Similarly, in December 2022, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its Eterna spinal cord stimulation (SCS) system, which is notable for being the smallest implantable, rechargeable spinal cord stimulator currently available for treating chronic pain. This innovative device utilizes Abbott's proprietary BurstDR stimulation technology, which has been shown to provide superior pain relief compared to traditional stimulation methods.

Thus, the above factors are consolidating the region's position as a dominant force in the global chronic pain market.

Asia Pacific is growing at the fastest pace in the global chronic pain market share

Asia Pacific holds the fastest pace in the global chronic pain market and is expected to hold most of the market share.

Chronic pain is a leading reason for individuals seeking medical care worldwide. However, in India, a significant portion of the population especially in rural areas struggles to access effective analgesic medications and comprehensive pain management solutions. This lack of access results in many people enduring their suffering in silence.

According to estimates from the World Health Organization (WHO), around 80% of patients experiencing severe pain globally do not receive adequate treatment. This highlights an urgent need for alternative pain management solutions, particularly in countries like India, where healthcare resources may be limited.

Innovations in healthcare technology are significantly transforming chronic pain management throughout the APAC region. The development of advanced pain management devices, telemedicine solutions, and digital health technologies has led to improved monitoring and personalized treatment plans. These advancements not only enhance patient engagement but also increase the effectiveness of managing chronic pain, thereby driving market growth.

Governments in the APAC region are actively implementing supportive policies aimed at enhancing healthcare access and quality. Initiatives that promote healthcare reforms and invest in medical infrastructure contribute to better availability of pain management resources. These efforts create a favorable environment for the growth of the chronic pain market by facilitating access to innovative treatments and technologies.

Additionally, government initiatives often focus on increasing awareness about chronic pain and its management among both healthcare providers and the general public. By promoting education and training programs, governments can help ensure that patients receive timely and effective treatment for their chronic pain conditions.

For instance, in November 2024, Pain Relief International, a registered 501(c)(3) non-profit organization recognized as a global leader in sustainable, drug-free pain relief technology, announced a significant initiative aimed at alleviating chronic pain in India. This initiative is particularly crucial given that an estimated 200 million people in the country suffer from ongoing pain, with many rural communities facing substantial barriers to effective pain management solutions. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global chronic pain market.

Competitive Landscape

The major global players in the chronic pain market include Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, Bayer AG, Novartis AG, Endo, Inc., Viatris Inc., Eli Lilly and Company., Teva Pharmaceutical Industries Ltd., and Reckitt Benckiser Group PLC among others.

Key Developments
• In November 2024, the launch of a dedicated operation theatre for pain management at KEM Hospital in Mumbai marks a significant advancement in the treatment of chronic pain conditions. This initiative reflects the growing recognition of pain management as a specialized field within healthcare, focusing on comprehensive strategies to alleviate persistent pain associated with various medical conditions.
• In September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of its HFX iQ spinal cord stimulation (SCS) system, which features the innovative HFX AdaptivAI technology. This new platform represents a significant advancement in personalized pain management for patients suffering from chronic pain.
• In September 2024, Hinge Health announced the launch of the Enso 3, a new FDA-cleared wireless device designed to provide effective relief for chronic musculoskeletal pain. This innovative device represents a significant advancement in pain management technology, offering a non-invasive, non-addictive solution that can deliver pain relief within minutes.
• In July 2024, Stryker launched the MultiGen 2 Radiofrequency Generator in India, a cutting-edge technology designed to enhance the management of chronic joint pain through radiofrequency ablation (RFA). This device provides physicians with greater control and customization during the RFA procedure, which is a minimally invasive technique used to alleviate pain.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global chronic pain market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.